Cutaneous leishmaniasis in a patient receiving infliximab for psoriatic arthritis: treatment with cryotherapy and intralesional meglumine antimonate
Actas Dermosifiliogr. 2014 Sep;105(7):714-6.
doi: 10.1016/j.ad.2013.08.011.
Epub 2013 Nov 22.
[Article in
English,
Spanish]
Affiliations
- 1 Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España. Electronic address: acatala@santpau.cat.
- 2 Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España.
- 3 Servicio de Microbiología, Hospital de la Santa Creu i Sant Pau, Barcelona, España.
No abstract available
MeSH terms
-
Adult
-
Antiprotozoal Agents / administration & dosage*
-
Antirheumatic Agents / adverse effects*
-
Antirheumatic Agents / therapeutic use
-
Arthritis, Psoriatic / drug therapy
-
Combined Modality Therapy
-
Cryotherapy*
-
Humans
-
Infliximab / adverse effects*
-
Infliximab / therapeutic use
-
Injections, Intralesional
-
Leishmaniasis, Cutaneous / chemically induced
-
Leishmaniasis, Cutaneous / therapy*
-
Male
-
Meglumine / administration & dosage*
-
Meglumine Antimoniate
-
Organometallic Compounds / administration & dosage*
Substances
-
Antiprotozoal Agents
-
Antirheumatic Agents
-
Organometallic Compounds
-
Meglumine
-
Meglumine Antimoniate
-
Infliximab